|
 The new scans are part of a large clinical trial called
Anti-Amyloid Treatment in Asymptomatic Alzheimer's or A4, the first
designed to identify and treat patients in the earliest stages of
Alzheimer's, before memory loss begins.
Patients accepted into the A4 trial already have deposits of beta
amyloid, the other protein associated with Alzheimer's. The addition
of the tau scan will allow scientists to get a much clearer picture
of the events that lead to Alzheimer's. The disease affects 5
million Americans, and 16 million are projected to be afflicted by
2050.
Dr. Reisa Sperling of Massachusetts General Hospital in Boston, who
is leading the 1,000-patient trial, said tau is commonly found in
small amounts in healthy people over age 70, but it is generally
confined to an area of the brain called the medial temporal lobe.
When amyloid is present, it somehow opens the door for tau to spread
to other parts of the brain, causing widespread cell death and
cognitive decline.
 "Tau is the actual bad actor on the front line that tears up the
brain. Being able to see it in living humans is a breakthrough,"
said Dr. Keith Johnson, director of molecular neuroimaging at
Massachusetts General, who is leading the imaging portion of the A4
trial.
In the study, patients will be offered treatments to remove amyloid
from the brain in the hopes of keeping tau in check.
Several companies have developed drugs aiming to remove amyloid and
alter the course of Alzheimer's, but all failed to show a
significant benefit. Sperling and other researchers believe that's
because the drugs were introduced too late after the onset of
disease.
In 2012, Eli Lilly's solanezumab failed to slow the disease in
patients with two trials of patients with mild to moderate symptoms.
But combined results showed the drug appeared to slow cognitive
decline by 34 percent among patients who started with only mild
symptoms.
[to top of second column] |
Patients in the A4 trial will be randomized to receive Lilly's
anti-amyloid drug or a placebo for about three years. Lilly is
funding the trial, along with the National Institutes of Health and
several philanthropic organizations. Researchers plan to do tau
imaging on up to 500 patients in the A4 trial. The tau imaging will
be paid for by the Accelerating Medicines Partnership, which is
sponsored by the National Institutes of Health and the Alzheimer's
Association.
Arthur Canter, 67, a retired executive from Boston, will be the
first A4 patient to be scanned for tau. Canter, who has a sharp
memory and quick wit, already has amyloid building up in his brain.
Canter gets his scan on Tuesday and fully expects it will show
deposits of tau forming as well. His mother, 91, has Alzheimer's,
and his father showed signs of dementia when he died in his 70s from
an unrelated condition.
"My assumption, predicated on my own genetics, is that I am likely
to be get Alzheimer's. In this regard, I'd rather hit it head on,"
he said.
(Reporting by Julie Steenhuysen; Editing by Michele Gershberg and
David Gregorio)
[© 2015 Thomson Reuters. All rights
reserved.]
Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
